Get the Stockscreener App
0.9494
3.25%
0.0299
Pre-market:
.95
0.0006
+0.06%
Cognition Therapeutics Inc stock is traded at $0.9494, with a volume of 400.42K.
It is up +3.25% in the last 24 hours and down -15.23% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$0.9195
Open:
$0.94
24h Volume:
400.42K
Relative Volume:
0.28
Market Cap:
$84.97M
Revenue:
-
Net Income/Loss:
$-19.58M
P/E Ratio:
-3.6841
EPS:
-0.2577
Net Cash Flow:
$-20.25M
1W Performance:
+0.08%
1M Performance:
-15.23%
6M Performance:
-28.08%
1Y Performance:
+13.02%
1-Day Range:
$0.9101
$0.9738
1-Week Range:
$0.91
$1.02
52-Week Range:
$0.5501
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.9494 | 84.97M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.941|Chg%:+0.021 - TradingKey
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.929|Chg%:+0.010 - TradingKey
Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr
Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative
Alzheimer’s drug developer to outline Lewy body dementia Phase 3 plan - Stock Titan
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit - GlobeNewswire
Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Number of shareholders of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa
Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo
Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index - marketscreener.com
Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33% - MSN
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index - marketscreener.com
Cognition, FDA agree on late-stage trial for dementia therapy - MSN
symbol__ Stock Quote Price and Forecast - CNN
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha
H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail
Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
CGTX Forecast — Price Target — Prediction for 2027 - TradingView
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Share RallyHealthcare Earnings Report - dars.gov.et
Cognition Therapeutics | 10-K: FY2025 Annual Report - Moomoo
FDA says DLB psychosis could be approvable in Cognition trial plan - Stock Titan
Cognition Therapeutics receives FDA alignment on Phase 3 trial of zervimesine for DLB psychosis - grafa.com
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% - TradingView
Cognition Therapeutics Secures FDA Alignment for Pivotal Phase 3 Trial of Zervimesine in DLB Psychosis, Targeting First Durable Treatment Option 1 – Minichart - Minichart
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) - Yahoo Finance
Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment - marketscreener.com
Cognition Therapeutics stock rises on FDA trial alignment By Investing.com - Investing.com Canada
Cognition Therapeutics aligned with FDA on pivotal Phase 3 design for zervimesine in DLB psychosis - TradingView
Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis - Quiver Quantitative
Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine - Stock Titan
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):